Jonas Grossmann

Jonas Grossmann

Auto-generated profile, based on publicly available information

Jonas Grossmann

Functional Genomics Center Zürich, University of Zürich/ETH Zürich, Zürich, Switzerland

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2008 in Science
Verified
Journal Article
Closed access
PDF file
KBKatja Baerenfaller
Katja Baerenfaller
JGJonas Grossmann
Jonas Grossmann
MGMonica A. Grobei
Monica A. Grobei
RHRoger Hull
Roger Hull
MHMatthias Hirsch-Hoffmann
Matthias Hirsch-Hoffmann
SBSacha Baginsky
Sacha Baginsky
We have assembled a proteome map for Arabidopsis thaliana from high-density, organ-specific proteome catalogs that we generated for different organs, developmental stages, and undifferentiated cultured cells. We matched 86,456 unique peptides to 13,029 proteins and provide expression evidence for 57 gene models that are not represented in the TAIR7 protein database. Analysis of the proteome identified organ-specific biomarkers and allowed us to compile an organ-specific set of proteotypic peptides for 4105 proteins to facilitate targeted quantitative proteomics surveys. Quantitative information for the identified proteins was used to establish correlations between transcript and protein accumulation in different plant organs. The Arabidopsis proteome map provides information about genome activity and proteome assembly and is available as a resource for plant systems biology.

1 August 2010 in Journal of Proteomics
Verified
Journal Article
Closed access
JGJonas Grossmann
Jonas Grossmann
BRBernd Roschitzki
Bernd Roschitzki
CPChristian Panse
Christian Panse
CFClaudia Fortes
Claudia Fortes
SBSimon Barkow-Oesterreicher
Simon Barkow-Oesterreicher
Ralph SchlapbachRalph Schlapbach
Ralph Schlapbach

1 April 2006 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
ANAlexey I. Nesvizhskii
Alexey I. Nesvizhskii
FRFranz F. Roos
Franz F. Roos
JGJonas Grossmann
Jonas Grossmann
MVMathijs Vogelzang
Mathijs Vogelzang
JEJames S. Eddes
James S. Eddes
RARuedi Aebersold
Ruedi Aebersold
In mass spectrometry-based proteomics, frequently hundreds of thousands of MS/MS spectra are collected in a single experiment. Of these, a relatively small fraction is confidently assigned to peptide sequences, whereas the majority of the spectra are not further analyzed. Spectra are not assigned to peptides for diverse reasons. These include deficiencies of the scoring schemes implemented in the database search tools, sequence variations (e.g. single nucleotide polymorphisms) or omissions in the database searched, post-translational or chemical modifications of the peptide analyzed, or the observation of sequences that are not anticipated from the genomic sequence (e.g. splice forms, somatic rearrangement, and processed proteins). To increase the amount of information that can be extracted from proteomic MS/MS datasets we developed a robust method that detects high quality spectra within the fraction of spectra unassigned by conventional sequence database searching and computes a quality score for each spectrum. We also demonstrate that iterative search strategies applied to such detected unassigned high quality spectra significantly increase the number of spectra that can be assigned from datasets and that biologically interesting new insights can be gained from existing data.

2 March 2020 in Nature Ecology & Evolution
Verified
Journal Article
Closed access
PDF file
SWShevan Wilkin
Shevan Wilkin
AMAlicia Ventresca Miller
Alicia Ventresca Miller
WTWilliam T. T. Taylor
William T. T. Taylor
BMBryan K. Miller
Bryan K. Miller
RHRichard W. Hagan
Richard W. Hagan
JHJessica Hendy
Jessica Hendy

11 October 2005 in Analytical Chemistry
Verified
Journal Article
Closed access
BFBernd Fischer
Bernd Fischer
VRVolker Roth
Volker Roth
FRFranz Roos
Franz Roos
JGJonas Grossmann
Jonas Grossmann
SBSacha Baginsky
Sacha Baginsky
JBJoachim M. Buhmann
Joachim M. Buhmann

1 July 2018 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
Nagihan BostanciNagihan Bostanci
Nagihan Bostanci
NSNathalie Selevsek
Nathalie Selevsek
WWWitold Wolski
Witold Wolski
JGJonas Grossmann
Jonas Grossmann
KBKai Bao
Kai Bao
Georgios BelibasakisGeorgios Belibasakis
Georgios Belibasakis
Periodontal diseases are among the most prevalent worldwide, but largely silent, chronic diseases. They affect the tooth-supporting tissues with multiple ramifications on life quality. Their early diagnosis is still challenging, due to lack of appropriate molecular diagnostic methods. Saliva offers a non-invasively collectable reservoir of clinically relevant biomarkers, which, if utilized efficiently, could facilitate early diagnosis and monitoring of ongoing disease. Despite several novel protein markers being recently enlisted by discovery proteomics, their routine diagnostic application is hampered by the lack of validation platforms that allow for rapid, accurate and simultaneous quantification of multiple proteins in large cohorts. Here we carried out a pipeline of two proteomic platforms; firstly, we applied open ended label-free quantitative (LFQ) proteomics for discovery in saliva (n = 67, including individuals with health, gingivitis, and periodontitis), followed by selected-reaction monitoring (SRM)-targeted proteomics for validation in an independent cohort (n = 82). The LFQ platform led to the discovery of 119 proteins with at least 2-fold significant difference between health and disease. The 65 proteins chosen for the subsequent SRM platform included 50 functionally related proteins derived from the significantly enriched processes of the LFQ data, 11 from literature-mining, and four house-keeping ones. Among those, 60 were reproducibly quantifiable proteins (92% success rate), represented by a total of 143 peptides. Machine-learning modeling led to a narrowed-down panel of five proteins of high predictive value for periodontal diseases with maximum area under the receiver operating curve >0.97 (higher in disease: Matrix metalloproteinase-9, Ras-related protein-1, Actin-related protein 2/3 complex subunit 5; lower in disease: Clusterin, Deleted in Malignant Brain Tumors 1). This panel enriches the pool of credible clinical biomarker candidates for diagnostic assay development. Yet, the quantum leap brought into the field of periodontal diagnostics by this study is the application of the biomarker discovery-through-verification pipeline, which can be used for validation in further cohorts.